Cosmetic Peptide High Purity Powder ARG-GLY-ASP CAS 99896-85-2 with Safe Delivery

Basic Information

Description
Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM), found in species ranging from Drosophila to humans. Cell adhesion proteins called integrins recognize and bind to this sequence, which is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins.

Useful

Use in Drug Discovery

Understanding of the molecular basis of binding to integrins has enabled the development of several drugs for cardiovascular disease and cancer, including eptifibatide, tirofiban, cilengitide, and the PET radiotracer fluciclatide.

Eptifibatide and tirofiban are anti-clotting drugs indicated to prevent thrombosis in acute ischemic coronary syndromes. They block activation of the integrin responsible for aggregation of platelets (αIIbβ3, also known as glycoprotein IIb/IIIa) in response to the blood glycoproteins fibrinogen and von Willebrand factor. Eptifibatide (marketed as Integrilin) is a cyclic (circular) seven amino acid peptide, whereas tirofiban is a small molecule designed to mimic the chemistry and binding affinity of the RGD sequence.

Cilengitide, a cyclic pentapeptide (RGDfV), is an investigational drug intended to block the growth of new blood vessels in tumors by interfering with the activation of integrin αVβ3. It has been evaluated for the treatment of glioblastoma, but, as is the case for other anti-angiogenic therapies, has not been shown to alter progression or improve survival either alone or in combination with standard treatments.

Fluciclatide, an ¹⁸F-labelled small peptide that binds to integrin αVβ3 and integrin αVβ5, is being tested as a tool to monitor treatment response of tumors to anti-angiogenic therapies.

CEND-1, also known as iRGD, is a cyclic peptide that homes to tumors via binding to Integrin alpha V receptors. However, it also binds and activates neuropilin-1, leading to a temporary opening of the tumor and an enhanced delivery of anti-cancer agents into the tumor tissue. It is currently being tested in clinical trials in solid tumor patients. 

Use in Bioengineering

RGD-based peptides have found many applications in biological research and medical devices. Culture plates coated with peptides mimicking ECM proteins' adhesion motifs, which restrict the differentiation of stem and progenitor cells, are on the market. RGD-coated implantable medical devices are under active study to enhance attachment of endothelial cells, which would help avoid the foreign body reaction. RGD is also a universally used tool in the construction of multifunctional "smart" materials, such as tumor-targeted nanoparticles.

Our Company
Wuhan Wujia Trading Co.,Ltd is a high-tech innovative enterprise specializing in the R & D, production and sales of API and pharmaceutical intermediates (excluding drugs). Our company is based on the optical valley biological city, with the help of Wuhan University Scientific Research Laboratory, making full use of the park policy advantages, focusing on the research and development of biological medicine. Our company always adheres to the business philosophy of "market demand oriented; technology research and development as the core competitiveness; e-commerce as the platform", more accurate, better, faster and more reliable to provide biomedical products for pharmaceutical units, university scientific research institutions, hospital outpatient service, reagent units, distributors in the world.